PRIMARY BILIARY CHOLANGITIS TREATMENT MARKET

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. PRIMARY BILIARY CHOLANGITIS TREATMENT MARKET Primary biliary cirrhosis, also known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis include itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat, and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and may cause the liver to stop working completely in later stages. The global primary biliary cholangitis treatment market size was valued at US$ 526.4 million in 2017, and is expected to witness a CAGR of 36.3% during the forecast period (2018 – 2026).

3. Figure 1. Global Primary Biliary Cholangitis Treatment Market Value Analysis (US$ Mn) and Forecast and Absolute $ Opportunity Source: Coherent Market Insights Analysis (2019)

4. Increasing number of pipeline studies is expected to drive the primary biliary cholangitis treatment market growth Increasing pipeline studies to develop prominent treatments for rare diseases such as primary biliary cholangitis are expected to boost the primary biliary cholangitis treatment market size. For instance, in October 2018, CymaBay Therapeutics, Inc., initiated placebo-controlled and randomized phase 3 clinical trial for seladelpar 5-10mg. The aim of the study was to evaluate safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and to determine inadequate response or intolerance to ursodeoxycholic acid (UDCA). The study is estimated to complete in December 2021. Moreover, in January 2017, GlaxoSmithKline (GSK) initiated phase 2 clinical trial to study the efficacy, safety, and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). GSK2330672 is a selective inhibitor of human ileal bile acid transporter (IBAT). The study is estimated to complete in April 2020.

5. Primary Biliary Cholangitis Treatment Market- Regional Analysis Regional segmentation of the global primary biliary cholangitis treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is anticipated to witness lucrative primary biliary cholangitis treatment market growth, owing to growing initiatives by market players to develop advance treatment options for PBC. For instance, in October 2016, TARGET PharmaSolutions, Inc., U.S.-based Company, in collaboration with Intercept Pharmaceuticals, Inc., launched its TARGET-PBC (Primary Biliary Cholangitis) platform. TARGET-PBC platform has been created to improve the understanding of real world treatment patterns in PBC. Asia Pacific is also expected to witness significant growth in the primary biliary cholangitis treatment market.

6. Figure 2: Global Primary Biliary Cholangitis Treatment Market Value (US$ Mn), By Region, 2017 Source: Coherent Market Insights Analysis (2019) Primary Biliary Cholangitis Treatment Market - Competitive Landscape Key players operating in the primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, Retrophin, Inc., Calliditas Therapeutics AB., and GlaxoSmithKline (GSK) pharmaceutical.

7. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. •  What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

8. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • CMI Services • CMI Latest Insights • CMI Blogs

9. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

10. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/